Theravance Biopharma, Inc. (TBPH) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Theravance Biopharma KOL event. At this time, all attendees are in a listen-only mode. A question and answer session will follow the formal presentations. As a reminder, this call is being recorded and a replay will be made available on the Theravance website following the conclusion of the event. I'd now like to turn the call over to Rick Winningham, Chief Executive Officer at Theravance Biopharma. Please go ahead, Rick. Good morning, and thank you for joining us. We're excited to host this KOL event focused on ampryloxetine, a medicine with an orphan drug designation. targeted to treat a rare neurologic disease, neurogenic orthostatic hypotension in patients with multiple system atrophy. Amproloxine is finishing a pivotal phase three study called Cypress, we'll refer to it during the course of the call, with data expected in the first quarter of 2026. Today's call is to describe the significant unmet need in symptomatic neurogenic orthostatic hypotension, or NOH, and again, patients with multiple system atrophy, or MSA, and to show why we believe amproloxetine has the potential to change the treatment landscape as a once-daily oral medicine with a durable treatment effect, creating value for patients and shareholders. Can you get the next slide, please? Before we begin, let me note that we'll be making forward-looking statements today involving risks and uncertainties related to our development pipeline, the expected benefits of our product candidate, and anticipated timing of clinical trials and regulatory filings and our expected financial results. You can find further information concerning the factors that could cause results to differ materially from these forward-looking statements in our filings with the SEC. Next slide, pleas...